- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01578499
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (ALCANZA)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat people who have CD30+ cutaneous T-cell lymphoma (mycosis fungoides and primary cutaneous anaplastic large cell lymphoma). This study will look at the overall response of people who took brentuximab vedotin compared to people who took methotrexate or bexarotene as standard care.
The study enrolled 131 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
- Methotrexate 5 to 50 mg or Bexarotene 300 mg/m^2 (as per physician's choice)
- Brentuximab vedotin 1.8 mg/kg
This multicenter trial is being conducted worldwide. The overall time to participate in this study is approximately 6 years. Participants will make multiple visits to the clinic every 12 weeks for a minimum of 24 months after the end of treatment (EOT) visit, and then every 6 months until death, study closure, or 6 years after enrollment of the last participant.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
East Melbourne, Australia
-
-
New South Wales
-
Concord, New South Wales, Australia
-
-
Queensland
-
South Brisbane, Queensland, Australia
-
-
South Australia
-
Adelaide, South Australia, Australia
-
-
Western Australia
-
Nedlands, Western Australia, Australia
-
-
-
-
-
St. Poelten, Austria
-
Wien, Austria
-
-
-
-
-
Leuven, Belgium
-
-
-
-
-
Sao Paulo, Brazil
-
-
-
-
-
Nantes Cedex 01, France
-
Paris, France
-
Pessac Cedex, France
-
Pierre Benite, France
-
Reims, France
-
-
-
-
-
Kiel, Germany
-
Krefeld, Germany
-
Mainz, Germany
-
Mannheim, Germany
-
Minden, Germany
-
Wurzburg, Germany
-
-
-
-
-
Bologna, Italy
-
Firenze, Italy
-
Meldola, Italy
-
-
-
-
-
Warszawa, Poland
-
-
-
-
-
Barcelona, Spain
-
Madrid, Spain
-
-
Navarra
-
Pamplona, Navarra, Spain
-
-
-
-
-
Zurich, Switzerland
-
-
-
-
-
Birmingham, United Kingdom
-
Glasgow, United Kingdom
-
London, United Kingdom
-
Manchester, United Kingdom
-
-
West Yorkshire
-
Leeds, West Yorkshire, United Kingdom
-
-
-
-
California
-
Los Angeles, California, United States
-
Palo Alto, California, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
New Jersey
-
Hackensack, New Jersey, United States
-
-
New York
-
New York, New York, United States
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Voluntary consent form
- Male or female participants 18 years or older with diagnosis of mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL)
- Participants with pcALCL who have received prior radiation therapy or at least 1 prior systemic therapy; participants with MF who have received at least 1 prior systemic therapy
- Histologically confirmed CD30+ disease by central laboratory assessment and pathology review
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant
- Male participants who agree to practice effective barrier contraception or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant
- Clinical laboratory values as specified in protocol
- A 3-week washout period is required from previous treatments (with the exception of a 12-week washout for antibody-directed or immunoglobulin-based immune therapy, or other monoclonal antibody therapies), unless it is not in the best interest of the patient in the opinion of the investigator. Individual cases should be discussed with the project clinician before enrollment.
Exclusion Criteria:
- A concurrent diagnosis of systemic ALCL, or other non Hodgkin lymphoma (excluding LyP) or Sezary syndrome or B2 disease
- Participants with cardiovascular conditions specified in protocols
- Participants with history of another primary malignancy not in remission for at least 3 years
- Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML);
- Known human immunodeficiency virus (HIV) infection, hepatitis B or Hepatitis C infection
- Oral retinoid therapy for any indication within 3 weeks of study entry
- Corticosteroid therapy within 3 weeks or immunosuppressive chemotherapy or any antibody-directed or immunoglobulin-based immune therapy (e.g., immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first dose of study drug
- Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 of any cycle
- Previous receipt of brentuximab vedotin Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Brentuximab vedotin
Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).
|
Brentuximab vedotin intravenous injection.
Other Names:
|
ACTIVE_COMPARATOR: Methotrexate or Bexarotene
Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m^2, tablets, orally, once daily with meals for up to 48 weeks.
|
Methotrexate tablets.
Bexarotene tablets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)
Time Frame: Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)
|
ORR4 was determined by an Independent Review Facility (IRF) based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic assessment by an IRF and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells.
Participants whose first response occurred after the start of subsequent anticancer therapy were excluded.
Response Criteria was based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and Cutaneous Lymphoma Task Force (CLTF) of the European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines (Olsen, 2011).
|
Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving a CR
Time Frame: Each Cycle until disease progression, death or data cutoff (Median overall follow-up 38.8 months)
|
Complete Response (CR) was determined by the IRF based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells.
Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
|
Each Cycle until disease progression, death or data cutoff (Median overall follow-up 38.8 months)
|
Progression-Free Survival (PFS)
Time Frame: Until disease progression, death or data cutoff (Median PFS follow-up of 38.8 months)
|
PFS was assessed by the IRF and is defined as the time from randomization until disease progression or death due to any cause, whichever occurs first.
Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
|
Until disease progression, death or data cutoff (Median PFS follow-up of 38.8 months)
|
Maximum Change From Baseline in Symptom Domain Score of the Skindex-29 Questionnaire
Time Frame: Baseline up to End of Treatment (Week 52)
|
Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL).
The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning.
The domain scores and an overall score are expressed on a 100-point scale, from 0 to 100 with higher scores indicating lower levels of health- HRQoL.
A negative change (reduction) from Baseline indicates improvement.
|
Baseline up to End of Treatment (Week 52)
|
Duration of Response (DOR)
Time Frame: Until disease progression, death or data cutoff (Median follow-up 38.8 months)
|
Duration of response was assessed by the IRF in participants with confirmed response [CR or Partial Response (PR)] and is defined as the time between first documentation of response and disease progression.
Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
|
Until disease progression, death or data cutoff (Median follow-up 38.8 months)
|
DOR of Skin Response
Time Frame: Until disease progression, death or data cutoff (Median follow-up 38.8 months)
|
Duration of skin response (CR and PR) was assessed by the investigator and is defined as the time between the first skin response to progressive disease in skin.
Per mSWAT, CR is defined as 100% clearance of skin lesions.
PR is defined as 50%-99% clearance of skin disease from Baseline; No new tumors in participants without tumors at Baseline -MF; No new tumors-primary cutaneous anaplastic large cell lymphoma (pcALCL).Progressive disease is defined as ≥ 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, or new tumors in participants without tumors at baseline (MF).
|
Until disease progression, death or data cutoff (Median follow-up 38.8 months)
|
Event-Free Survival (EFS)
Time Frame: From randomization until disease progression, death or data cutoff (Median follow-up 36.8 months)
|
EFS was assessed by the IRF and is defined as the time from randomization until any cause of treatment failure: disease progression, discontinuation of treatment for any reason, or death due to any cause, whichever occurs first.
Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
|
From randomization until disease progression, death or data cutoff (Median follow-up 36.8 months)
|
Cmax: Maximum Observed Concentration for Brentuximab Vedotin
Time Frame: Day 1 pre-dose and 30 minutes after infusion in Cycles 1 and 3
|
Day 1 pre-dose and 30 minutes after infusion in Cycles 1 and 3
|
|
Ctrough: Observed Concentration at the End of a Dosing Interval for Brentuximab Vedotin
Time Frame: Day 1 pre-dose of Cycles 2 and 4
|
Day 1 pre-dose of Cycles 2 and 4
|
|
Cmax: Maximum Observed Concentration for Monomethyl Auristatin (MMAE) for Brentuximab Vedotin
Time Frame: Day 1 pre-dose and 30 minutes after infusion ended in Cycles 1 and 3
|
Day 1 pre-dose and 30 minutes after infusion ended in Cycles 1 and 3
|
|
Ctrough: Observed Concentration at the End of a Dosing Interval for MMAE for Brentuximab Vedotin
Time Frame: Day 1 pre-dose of Cycles 2 and 4
|
Day 1 pre-dose of Cycles 2 and 4
|
|
Number of Participants With Antitherapeutic Antibodies (ATA) to Brentuximab Vedotin
Time Frame: Baseline up to End of Treatment (Week 52)
|
Blood was collected and evaluated for ATA and neutralizing ATA in all participants who received brentuximab vedotin to assess immunogenicity.
|
Baseline up to End of Treatment (Week 52)
|
Change From Baseline in the Skindex-29 Questionnaire Total Score
Time Frame: Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at End of Treatment (EOT) and during posttreatment long treatment follow-up (LTFU) - (Median follow-up 38.8 months)
|
Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL).
The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning.
The domain scores and an overall score are expressed on a 100-point scale, 0 to 100 with higher scores indicating lower levels of health- HRQoL.
A negative change (reduction) from Baseline indicates improvement.
|
Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at End of Treatment (EOT) and during posttreatment long treatment follow-up (LTFU) - (Median follow-up 38.8 months)
|
Change From Baseline in Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) Score
Time Frame: Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at EOT and during posttreatment (LTFU) - (Median follow-up 38.8 months)
|
FACT-G is a 27-item general cancer QOL instrument completed by participants receiving cancer treatment.
FACT-G incorporates a 7-day recall period and contains 4 primary subscales: Physical Well-Being (PWB; sum of 7 items, point range 0-28); Social/Family Well-Being (SWB, sum of 7-items, point range 0-28); Emotional Well-Being (EWB; sum of 6-items, point range 0-24); Functional Well-Being (FWB; sum of 7-items, point range 0-28); Fact-G total score=sum of PWB, SWB, EWB, FWB, point range 0-108.
Higher scores for the total scales and subscales indicate better quality of life.
A negative change (reduction) from Baseline indicates improvement.
|
Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at EOT and during posttreatment (LTFU) - (Median follow-up 38.8 months)
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: First dose of study drug through 30 days after last dose of study drug (Up to 450 days)
|
AEs and SAEs were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
A SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.
|
First dose of study drug through 30 days after last dose of study drug (Up to 450 days)
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710.
- Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, Sanches JA, Stadler R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown LC, Ortiz-Romero PL, Akilov OE, Trotman J, Taylor K, Weichenthal M, Walewski J, Fisher D, McNeeley M, Gru AA, Brown L, Palanca-Wessels MC, Lisano J, Onsum M, Bunn V, Little M, Trepicchio WL, Dummer R. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. Eur J Cancer. 2021 May;148:411-421. doi: 10.1016/j.ejca.2021.01.054. Epub 2021 Mar 29.
- Valipour A, Jager M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD008946. doi: 10.1002/14651858.CD008946.pub3.
- Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer. 2020 Jul;133:120-130. doi: 10.1016/j.ejca.2020.04.010. Epub 2020 Jun 2.
- Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dreno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7.
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Bacterial Infections and Mycoses
- Lymphoma
- Mycoses
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell, Cutaneous
- Mycosis Fungoides
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
- Brentuximab Vedotin
- Bexarotene
Other Study ID Numbers
- C25001
- 2010-024215-14 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mycosis Fungoides
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Stage I Mycosis Fungoides | Stage II Mycosis Fungoides | Stage III Mycosis FungoidesUnited States
-
National Cancer Institute (NCI)Active, not recruitingMycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 | Recurrent Mycosis Fungoides... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingSezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Transformed Mycosis Fungoides | Folliculotropic... and other conditionsUnited States
-
Northwestern UniversityAmgenTerminatedRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IA Mycosis Fungoides/Sezary Syndrome | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...WithdrawnRecurrent Mycosis Fungoides and Sezary Syndrome | Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IIB Mycosis Fungoides and Sezary Syndrome | Stage IIIA Mycosis Fungoides and Sezary Syndrome | Stage IIIB Mycosis Fungoides and Sezary Syndrome | Stage IVA Mycosis Fungoides and Sezary Syndrome | Stage...
-
Rochester Skin Lymphoma Medical Group, PLLCRochester General HospitalCompletedMycosis Fungoides | Cutaneous T-cell Lymphoma | Transformed Mycosis Fungoides | Cutaneous T-cell Lymphoma Stage I | Folliculotropic Mycosis Fungoides | Granulomatous Slack Skin | Syringotropic Mycosis Fungoides | Mycosis Fungoides VariantUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingMycosis Fungoides | Sezary Syndrome | Mycosis Fungoides/Sezary Syndrome | Sézary | Advanced Mycosis FungoidesUnited States
Clinical Trials on Brentuximab Vedotin
-
Seagen Inc.TerminatedSystemic Lupus ErythematosusUnited States
-
University Hospital, CaenRecruiting
-
Washington University School of MedicineSeagen Inc.CompletedMyelodysplastic Syndromes | Leukemia, Acute Myeloid | Leukemia, Lymphoblastic,AcuteUnited States
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, France
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, Germany
-
Seagen Inc.Millennium Pharmaceuticals, Inc.No longer availableLymphoma, Non-Hodgkin | Lymphoma, T-Cell, Cutaneous | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, United Kingdom, Belgium, Serbia, Australia, Bulgaria, France, Germany, Hungary, Italy, Poland, Romania, Russian Federation, Spain, Switzerland
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterCompletedRelapsed or Refractory EBV-and CD30-positive LymphomasKorea, Republic of
-
Samsung Medical CenterMillennium Pharmaceuticals, Inc.CompletedNon-Hodgkin LymphomaKorea, Republic of
-
Fondazione Italiana Linfomi ONLUSCompletedRelapsed/Refractory Hodgkin's LymphomaItaly
-
Seagen Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States